REG - Thruvision Group PLC - Director Share Dealing-correction & further trade

ThruvisionAnnouncement

06/05/2022 12:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220506:nRSF6447Ka&default-theme=true

RNS Number : 6447K  Thruvision Group PLC  06 May 2022

6 May  2022

 

Thruvision Group plc

 

("Thruvision" or the "Company")

 

Director Share Dealing-correction and further trade

 

Thruvision (AIM:THRU), the leading provider of "safe distance"
people-screening technology to the international security market, provides an
update to the announcement made on 20 April 2022 regarding the share purchase
by Katrina Nurse, a Non-Executive Director of Thruvision, and her spouse, Mark
Nurse, a Closely Associated Person.

 

In that announcement, it was stated that 67,000 Thruvision shares were
purchased by each of Katrina Nurse and Mark Nurse at a price of 29.9p per
share. The price was incorrectly stated and should have been reported as 32p
per share.

 

In addition, Mark Nurse sold 9,591 Thruvision shares on 3 May 2022 at a price
of 33.1p per share. This transaction was triggered by an automatic process
within the fund in which the shares are held and was not intentional.
Accordingly, Mark Nurse re-purchased 9,591 Thruvision shares on 4 May 2022 at
a price of 33.5p per share.

 

Following these transactions, the beneficial shareholding in the Company of
Katrina Nurse and her closely Associated Persons remains unchanged at 134,000
Thruvision shares, representing 0.09% of the Company's total issued share
capital and total voting rights.

 

The notifications below, made in accordance with the requirements of the
Market Abuse Regulation, provides further detail:

 

 1.   Details of the person discharging managerial responsibilities/person closely
      associated
 (a)  Name                                             Mark Nurse, spouse of Katrina Nurse
 2.   Reason for the notification
 (a)  Position/status                                  Closely Associated Person of Katrina Nurse, a Non-Executive Director
 (b)  Initial notification/ Amendment                  Initial notification
 3.   Details of the issuer
 (a)  Name                                             Thruvision Group plc
 (b)  LEI                                              213800IZG9GM6G2TZE04
 4.   Details of the transaction(s): section to be repeated for (i) each type of
      instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted
 (a)  Description of the Financial Instrument          Ordinary shares of £0.01 each
 (b)  Identification code of the Financial Instrument  GB00B627R876
 (c)  Nature of the transaction                        Sale of shares

 (d)  Price(s) and volume(s)                           Price(s)                             Volume(s)
                                                       33.1p                                9,591

 (e)  Aggregated information                           N/A

      -           Aggregated volume

      -           Price
 (f)  Date of the transaction                          3 May 2022
 (g)  Place of the transaction                         London Stock Exchange

 

 

 

 

 1.   Details of the person discharging managerial responsibilities/person closely
      associated
 (a)  Name                                             Mark Nurse, spouse of Katrina Nurse
 2.   Reason for the notification
 (a)  Position/status                                  Closely Associated Person of Katrina Nurse, a Non-Executive Director
 (b)  Initial notification/ Amendment                  Initial notification
 3.   Details of the issuer
 (a)  Name                                             Thruvision Group plc
 (b)  LEI                                              213800IZG9GM6G2TZE04
 4.   Details of the transaction(s): section to be repeated for (i) each type of
      instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted
 (a)  Description of the Financial Instrument          Ordinary shares of £0.01 each
 (b)  Identification code of the Financial Instrument  GB00B627R876
 (c)  Nature of the transaction                        purchase of shares

 (d)  Price(s) and volume(s)                           Price(s)                             Volume(s)
                                                       33.5p                                9,591

 (e)  Aggregated information                           N/A

      -           Aggregated volume

      -           Price
 (f)  Date of the transaction                          4 May 2022
 (g)  Place of the transaction                         London Stock Exchange

 

 

 

For further information please contact:

 

Thruvision Group plc
                               +44 (0)1235 425400

Tom Black, Executive Chairman

Colin Evans, Chief Executive

 

Investec Investment Banking (NOMAD & Broker)
 +44 (0)20 7597 5970

Patrick Robb / James Rudd / Sebastian Lawrence

 

FTI Consulting
LLP
+44 (0)20 3727 1000

Matt Dixon

Tom Blundell

 

About Thruvision

Addressing the urgent need for "safe distance" people security screening in
the COVID era, Thruvision is uniquely capable of detecting metallic and
non-metallic items including weapons, explosives and contraband items that are
hidden under clothing, at distances between 3 and 10m. Using patented passive
terahertz technology, Thruvision completely removes the need for physical
"pat-downs" and has been vetted and approved by the US Transportation Security
Administration for surface transportation. Operationally deployed in 20
countries around the world, Thruvision is used for aviation security, retail
supply chain loss prevention, customs and border control, and public area
security. The company has offices near Oxford and Washington DC.

 

 

www.thruvision.com (http://www.thruvision.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHEAFSKEFEAEFA